Belviq (lorcaserin) was a prescription medication used for weight management in adults with obesity or overweight-related health conditions. Like all medications, Belviq was associated with a range of side effects, from mild and common to rare but serious. Understanding these side effects is essential for patients and healthcare providers to weigh the benefits and risks of therapy.
Common Side Effects
Most patients experienced mild to moderate side effects, especially during the early weeks of treatment. The most frequently reported included:
-
Headache
-
Dizziness
-
Fatigue or excessive tiredness
-
Nausea
-
Dry mouth
-
Constipation
-
Diarrhea
-
Back pain
-
Muscle pain or spasms
-
Cough
-
Insomnia (difficulty sleeping)
-
Decreased appetite
-
Urinary tract infection
-
Seasonal allergy symptoms
-
Eye disorders (such as blurred vision or dry eyes)
These symptoms were generally manageable and often subsided as the body adjusted to the medication.
Serious and Less Common Side Effects
Some patients experienced more severe or less common side effects, which required prompt medical attention:
-
Allergic reactions: Rash, hives, swelling of the face, lips, tongue, or throat, difficulty breathing or swallowing.
-
Mood or mental changes: New or worsening depression, suicidal thoughts, hallucinations, confusion, memory problems, difficulty concentrating, agitation, or feeling “outside your body”.
-
Heart-related issues: Slow heartbeat, irregular heartbeat, high blood pressure, or symptoms of heart valve problems (such as swelling, shortness of breath, or chest pain).
-
Painful or frequent urination
-
Nipple discharge or breast enlargement in males
-
Prolonged, painful erections (priapism)
-
Muscle spasms, stiffness, or twitching
-
Coordination difficulties
-
Excessive sweating or fever
-
Swelling of hands, arms, feet, or legs
-
Restlessness or agitation.
Rare but Severe Risks
Serotonin Syndrome
Belviq increases serotonin activity in the brain. When combined with other serotonergic drugs (such as certain antidepressants, migraine medications, or supplements), there is a risk of serotonin syndrome—a potentially life-threatening condition. Symptoms include agitation, confusion, rapid heart rate, high blood pressure, fever, muscle rigidity, shivering, sweating, severe diarrhea, and seizure.
Neuroleptic Malignant Syndrome (NMS)
This rare but serious disorder is characterized by fever, muscle stiffness, altered mental status, and autonomic dysfunction. It requires immediate medical attention.
Valvular Heart Disease
Belviq, like some older weight-loss drugs, has been associated with heart valve problems. Symptoms may include swelling, shortness of breath, or new heart murmurs. Regular monitoring was recommended during treatment.
Hypoglycemia
In patients with diabetes, Belviq can increase the risk of low blood sugar, especially when used with other diabetes medications. Symptoms include shakiness, sweating, confusion, and, in severe cases, loss of consciousness.
Cognitive Impairment
Some patients reported memory problems, confusion, difficulty concentrating, and other cognitive changes.
Cancer Risk
A long-term clinical trial found a possible increased risk of cancer among Belviq users compared to placebo. Types of cancer observed included pancreatic, colorectal, and lung cancers. While a direct causal relationship was not established, this concern contributed to the drug’s withdrawal from the market.
Monitoring and Patient Guidance
Regular Medical Monitoring
Because of the potential for serious side effects, patients taking Belviq required regular medical check-ups. Healthcare providers typically monitored:
-
Weight loss progress: To ensure the medication was effective. If a patient did not lose at least 5% of their starting body weight after 12 weeks, discontinuation was recommended.
-
Heart health: Periodic echocardiograms or other heart assessments were sometimes performed to watch for signs of valvular heart disease, especially in patients with symptoms like shortness of breath or swelling.
-
Blood sugar levels: For patients with diabetes, more frequent blood glucose monitoring was necessary due to the risk of hypoglycemia.
-
Mental health: Patients were advised to report any mood changes, depression, or suicidal thoughts immediately.
Other Considerations
-
Drug Interactions: Belviq can interact with medications that affect serotonin levels, increasing the risk of serotonin syndrome. Caution was also advised with drugs metabolized by CYP 2D6 enzymes.
-
Pregnancy and Breastfeeding: Belviq was not recommended during pregnancy due to potential harm to the fetus. It was also not known whether it was excreted in breast milk.
-
Discontinuation: In clinical trials, more patients taking Belviq discontinued therapy due to adverse effects compared to those on placebo. The most common reasons were headache, dizziness, fatigue, and nausea.
Conclusion
Belviq was associated with a spectrum of side effects, ranging from mild symptoms like headache and nausea to serious risks such as serotonin syndrome, heart valve disease, cognitive changes, and a possible increased risk of cancer. The potential for severe adverse effects, particularly the cancer risk, ultimately led to Belviq’s withdrawal from the market. Patients who were prescribed Belviq were advised to report any unusual or severe symptoms to their healthcare provider promptly and to seek alternatives for weight management when necessary.
